SmartTab's oral capsule for colon targeted drug delivery. Designed specifically for targeted delivery of medication.
Successfully Completed PK Pre-clinical Animal Studies in 2019. Preparing for Human Clinical Studies to begin Q4 2020. FDA submission Q2 2021. Anticipated FDA approval/clearance Q4 2021. Commercialization of prescription drug 2022.
SmartTab's oral injection capsule for biologics and large molecules. Making injections with needles a thing of the past.
Preparing PK Pre-clinical Animal Studies in a significant strategic partnership with a large pharmaceutical company begins Q3 2020. Human Clinical Studies to begin Q1 2021. FDA submission Q4 2021. Anticipated FDA approval/clearance and commercialization of prescription drug 2023.
SmartTab's multi-compartment capsule to reside in the stomach for a week with active ingredients to release each day.
Early design and prototyping complete. PK Pre-clinical Animal Studies to begin Q2 2021. Human Clinical Studies Q4 2021. FDA submission Q2 2022. Anticipated FDA approval/clearance and commercialization of prescription drug 2024.
The SmartTab platform utilizes inductive power (no on-board batteries) and proprietary innovative smart polymer technology for the actuation and release system. We continue to advance the capabilities of wireless power for the future of digital medicine.
The SmartTab platform connects with a smartphone or smartwatch via bluetooth RF signal to monitor when the capsule has reached the desired location. Monitoring for statistical based therapy optimization. Real-time decision making and wireless drug delivery.
We are developing superior drug delivery mechanisms. Using technology for an advanced drug delivery system that target's precise locations in the GI tract. When the triggering signal is sent, it releases immediately for better drug efficacy and better patient outcomes.
One of the biggest problems with treatments today is compliance. With the SmartTab electronic system triggering the release, the physician knows whether the patient is adhering to the prescribed drug treatment regimen.
By having a very specific targeted delivery system we can negate the negative side effects associated with the medicine and will be able to use lower dosages. Lower dosages means lower side effects and improved patient outcomes.
Integration with IoMT. Data can be sent into artificial intelligence and then optimize the treatment. The SmartTab platform will integrate with other systems as the future of digital health evolves.
TargetTab™ an ingestible capsule for wireless, targeted drug delivery. The first application of the SmartTab Platform for Crohn's and other GI related diseases.
